SCHEMBL412288

SCHEMBL412288

O=C(O)CCC/C=C\CCCCCCC/C=C\CCCCCO

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.65
FFAR1 O14842 1/20 0.65
FFAR4 Q5NUL3 1/20 0.65
TOP1 P11387 3/20 0.64
PPARG P37231 5/20 0.61
PPARD Q03181 4/20 0.61
PPARA Q07869 4/20 0.61
TERT O14746 3/20 0.61
PTPN1 P18031 3/20 0.61
MAPT P10636 3/20 0.61
BLM P54132 3/20 0.61
HSD17B10 Q99714 3/20 0.61
FABP4 P15090 3/20 0.61
F7 P08709 2/20 0.61
F3 P13726 2/20 0.61
USP2 O75604 2/20 0.61
LMNA P02545 2/20 0.61
ALOX15 P16050 2/20 0.61
RECQL P46063 2/20 0.61
CYP19A1 P11511 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8984505 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL8984507 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL31382568 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL14224944 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL1946239 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL8984474 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL14270521 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL8984470 1.00 GPR84 (0.65) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL4744794 0.98 GPR84 (0.61) GPR84FFAR1FFAR4TOP1PPARG
SCHEMBL23225824 0.95 FFAR1 (0.73) GPR84FFAR1FFAR4TOP1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029131-A2 METHOD FOR TREATING RENAL DISEASE M.C.W. Research Foundation, Inc. (US) 2009-03-04 EP claimed
US-20080306155-A1 METHOD FOR TREATING RENAL DISEASE ROMAN RICHARD J 2008-12-11 US claimed
WO-2007146262-A2 METHOD FOR TREATING RENAL DISEASE MCW RESEARCH FOUNDATION, INC. (US) 2007-12-21 WO claimed
US-20070004802-A1 Method for treating renal disease THE MEDICAL COLLEGE OF WISCONSIN, INC. 2007-01-04 US claimed
US-20060063836-A1 Method for treating renal disease NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-03-23 US claimed
EP-1056449-B1 20-HETE ANTAGONISTS AND AGONISTS MCW RES FOUND INC (US) 2003-04-16 EP claimed
US-20120021519-A1 EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) 2012-01-26 US disclosed
WO-2010033906-A2 EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-03-25 WO disclosed
EP-2029131-A2 METHOD FOR TREATING RENAL DISEASE M.C.W. Research Foundation, Inc. (US) 2009-03-04 EP disclosed
US-20080306155-A1 METHOD FOR TREATING RENAL DISEASE ROMAN RICHARD J 2008-12-11 US disclosed
US-20080306155-A1 METHOD FOR TREATING RENAL DISEASE ROMAN RICHARD J 2008-12-11 US disclosed
US-20080051454-A1 Compositions and methods for transient receptor potential vanilloid (TRPV) channel mediated treatments THE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2008-02-28 US disclosed
US-20080051454-A1 Compositions and methods for transient receptor potential vanilloid (TRPV) channel mediated treatments THE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2008-02-28 US disclosed
US-6395781-B1 REDUCING VASCULAR DIAMETER MCW RESEARCH FOUNDATION 2002-05-28 US disclosed
US-6395781-B1 REDUCING VASCULAR DIAMETER MCW RESEARCH FOUNDATION 2002-05-28 US disclosed
US-20020049244-A1 20-HETE antagonists and agonists NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-04-25 US disclosed
US-20020049244-A1 20-HETE antagonists and agonists NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-04-25 US disclosed
EP-1056449-A2 20-HETE ANTAGONISTS AND AGONISTS MCW Research Foundation, Inc. (US) 2000-12-06 EP disclosed
WO-1999043310-A3 20-HETE ANTAGONISTS AND AGONISTS MCW RES FOUND INC (US) 1999-10-07 WO disclosed
WO-1999043310-A2 20-HETE ANTAGONISTS AND AGONISTS MCW RESEARCH FOUNDATION, INC. (US) 1999-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306155-A1 METHOD FOR TREATING RENAL DISEASE ALOX15, ALOX5, ALOX15B GPR84 1022/4885FFAR1 240/4885FFAR4 433/4885
US-20020049244-A1 20-HETE antagonists and agonists ALOX5, ALOX15, ALOX15B GPR84 174/4885FFAR1 78/4885FFAR4 47/4885
US-20080051454-A1 Compositions and methods for transient receptor potential vanilloid (TRPV) channel mediated treatments TRPV1, TRPV3, TRPV5 GPR84 165/4885FFAR1 86/4885FFAR4 78/4885
US-20060063836-A1 Method for treating renal disease ALOX5, ALOX15, REN GPR84 869/4885FFAR1 231/4885FFAR4 416/4885
US-20070004802-A1 Method for treating renal disease ALOX15, ALOX15B, ALOX5 GPR84 836/4885FFAR1 42/4885FFAR4 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.